# Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

> **NCT00004057** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** L-778,123
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00004057
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** 2000-12
- **Final completion:** 2000-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004057, "Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*